{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:48:35Z","timestamp":1789674515104,"version":"4.0.1"},"reference-count":40,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"name":"Biogen Idec Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Neurol Scand"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1111\/ane.12475","type":"journal-article","created":{"date-parts":[[2015,9,8]],"date-time":"2015-09-08T06:28:46Z","timestamp":1441693726000},"page":"391-397","source":"Crossref","is-referenced-by-count":25,"title":["Anti-JC virus seroprevalence in a Finnish MS cohort"],"prefix":"10.1155","volume":"133","author":[{"given":"M.","family":"Kolasa","sequence":"first","affiliation":[{"name":"Neuroimmunology Unit; Medical School; University of Tampere; Tampere Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hagman","sequence":"additional","affiliation":[{"name":"Neuroimmunology Unit; Medical School; University of Tampere; Tampere Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Verkkoniemi-Ahola","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences; Helsinki University Central Hospital; Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Airas","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences; Turku University Hospital; Turku Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Koivisto","sequence":"additional","affiliation":[{"name":"Department of Neurology; Sein\u00e4joki Central Hospital; Sein\u00e4joki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Elovaara","sequence":"additional","affiliation":[{"name":"Neuroimmunology Unit; Medical School; University of Tampere; Tampere Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,9,8]]},"reference":[{"key":"10.1111\/ane.12475-BIB0001|ane12475-cit-0001","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1128\/CMR.05031-11","article-title":"Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain","volume":"25","author":"Ferenczy","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"10.1111\/ane.12475-BIB0002|ane12475-cit-0002","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1146\/annurev.med.080708.082655","article-title":"Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies","volume":"61","author":"Major","year":"2010","journal-title":"Annu Rev Med"},{"key":"10.1111\/ane.12475-BIB0003|ane12475-cit-0003","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s13365-013-0222-6","article-title":"Immune surveillance and response to JC virus infection and PML","volume":"20","author":"Beltrami","year":"2014","journal-title":"J Neurovirol"},{"key":"10.1111\/ane.12475-BIB0004|ane12475-cit-0004","first-page":"71","article-title":"Molecular biology and pathogenesis of human polyomavirus infections","volume":"94","author":"Dorries","year":"1998","journal-title":"Dev Biol Stand"},{"key":"10.1111\/ane.12475-BIB0005|ane12475-cit-0005","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/1352458513477925","article-title":"Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort","volume":"19","author":"Olsson","year":"2013","journal-title":"Mult Scler"},{"issue":"Pt 7","key":"10.1111\/ane.12475-BIB0006|ane12475-cit-0006","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1099\/vir.0.020115-0","article-title":"Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians","volume":"91","author":"Antonsson","year":"2010","journal-title":"J Gen Virol"},{"key":"10.1111\/ane.12475-BIB0007|ane12475-cit-0007","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1086\/595299","article-title":"Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study","volume":"199","author":"Engsig","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1111\/ane.12475-BIB0008|ane12475-cit-0008","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1111\/ane.12475-BIB0009|ane12475-cit-0009","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(11)70274-5","article-title":"Clinically isolated syndromes","volume":"11","author":"Miller","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1111\/ane.12475-BIB0010|ane12475-cit-0010","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald Criteria\u201d","volume":"58","author":"Polman","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1111\/ane.12475-BIB0011|ane12475-cit-0011","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1111\/ane.12475-BIB0012|ane12475-cit-0012","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jcv.2013.02.002","article-title":"A second-generation ELISA (STRATIFY JCV DxSelect) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification","volume":"57","author":"Lee","year":"2013","journal-title":"J Clin Virol"},{"key":"10.1111\/ane.12475-BIB0013|ane12475-cit-0013","unstructured":"Focus Diagnostics, Cypress, California, USA www.focusdx.com\/pdfs\/pi\/US\/EL1950.pdf"},{"key":"10.1111\/ane.12475-BIB0014|ane12475-cit-0014","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/ene.12304","article-title":"Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial","volume":"21","author":"Bozic","year":"2014","journal-title":"Eur J Neurol"},{"key":"10.1111\/ane.12475-BIB0015|ane12475-cit-0015","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1002\/jmv.21493","article-title":"Investigation of pre-diagnostic virological markers for progressive multifocal leukoencephalopathy in human immunodeficiency virus-infected patients","volume":"81","author":"Grabowski","year":"2009","journal-title":"J Med Virol"},{"key":"10.1111\/ane.12475-BIB0016|ane12475-cit-0016","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/ana.22606","article-title":"Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1","volume":"70","author":"Bozic","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1111\/ane.12475-BIB0017|ane12475-cit-0017","doi-asserted-by":"crossref","first-page":"e1000363","DOI":"10.1371\/journal.ppat.1000363","article-title":"Seroepidemiology of human polyomaviruses","volume":"5","author":"Kean","year":"2009","journal-title":"PLoS Pathog"},{"key":"10.1111\/ane.12475-BIB0018|ane12475-cit-0018","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1212\/WNL.0b013e3182583022","article-title":"Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort","volume":"78","author":"Trampe","year":"2012","journal-title":"Neurology"},{"key":"10.1111\/ane.12475-BIB0019|ane12475-cit-0019","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/jmv.10450","article-title":"Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40","volume":"71","author":"Knowles","year":"2003","journal-title":"J Med Virol"},{"key":"10.1111\/ane.12475-BIB0020|ane12475-cit-0020","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.22128","article-title":"Anti-JC virus antibodies: implications for PML risk stratification","volume":"68","author":"Gorelik","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1111\/ane.12475-BIB0021|ane12475-cit-0021","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1007\/s00415-012-6487-5","article-title":"Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy","volume":"259","author":"Outteryck","year":"2012","journal-title":"J Neurol"},{"key":"10.1111\/ane.12475-BIB0022|ane12475-cit-0022","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1136\/jnnp-2012-304332","article-title":"Changes to anti-JCV antibody levels in a Swedish national MS cohort","volume":"84","author":"Warnke","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1111\/ane.12475-BIB0023|ane12475-cit-0023","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1177\/1352458513477229","article-title":"Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients","volume":"19","author":"Selter","year":"2013","journal-title":"Mult Scler"},{"key":"10.1111\/ane.12475-BIB0024|ane12475-cit-0024","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000302687","article-title":"Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells","volume":"63","author":"Putzki","year":"2010","journal-title":"Eur Neurol"},{"key":"10.1111\/ane.12475-BIB0025|ane12475-cit-0025","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1212\/01.wnl.0000327671.91357.96","article-title":"Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis","volume":"71","author":"Krumbholz","year":"2008","journal-title":"Neurology"},{"key":"10.1111\/ane.12475-BIB0026|ane12475-cit-0026","doi-asserted-by":"crossref","first-page":"e103716","DOI":"10.1371\/journal.pone.0103716","article-title":"Effect of natalizumab treatment on circulating plasmacytoid dendritic cells: a cross-sectional observational study in patients with multiple sclerosis","volume":"9","author":"Kivisakk","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1111\/ane.12475-BIB0027|ane12475-cit-0027","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti-JCV antibody levels in serum or plasma further define risk of natalizumab-associated PML","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1111\/ane.12475-BIB0028|ane12475-cit-0028","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.virol.2012.06.010","article-title":"Cooperative roles of NF-kappaB and NFAT4 in polyomavirus JC regulation at the KB control element","volume":"432","author":"Wollebo","year":"2012","journal-title":"Virology"},{"key":"10.1111\/ane.12475-BIB0029|ane12475-cit-0029","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jneuroim.2006.03.004","article-title":"IL-6 and CCL2 levels in CSF are associated with the clinical course of MS: implications for their possible immunopathogenic roles","volume":"175","author":"Malmestrom","year":"2006","journal-title":"J Neuroimmunol"},{"key":"10.1111\/ane.12475-BIB0030|ane12475-cit-0030","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.3892\/mmr.2013.1256","article-title":"Cytokine profile in relapsing-remitting multiple sclerosis patients and the association between progression and activity of the disease","volume":"7","author":"Kallaur","year":"2013","journal-title":"Mol Med Rep"},{"key":"10.1111\/ane.12475-BIB0031|ane12475-cit-0031","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/1742-2094-9-215","article-title":"Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis","volume":"9","author":"Romme Christensen","year":"2012","journal-title":"J Neuroinflammation"},{"key":"10.1111\/ane.12475-BIB0032|ane12475-cit-0032","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.pharmthera.2004.11.007","article-title":"Cytokines in multiple sclerosis: from bench to bedside","volume":"106","author":"Imitola","year":"2005","journal-title":"Pharmacol Ther"},{"key":"10.1111\/ane.12475-BIB0033|ane12475-cit-0033","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1177\/1352458513505353","article-title":"JC-virus seroconversion in multiple sclerosis patients receiving natalizumab","volume":"20","author":"Outteryck","year":"2014","journal-title":"Mult Scler"},{"key":"10.1111\/ane.12475-BIB0034|ane12475-cit-0034","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s11481-013-9496-y","article-title":"Anti-JCV antibodies detection and JCV DNA levels in PBMC, serum and urine in a cohort of Spanish Multiple Sclerosis patients treated with natalizumab","volume":"8","author":"Dominguez-Mozo","year":"2013","journal-title":"J Neuroimmune Pharmacol"},{"key":"10.1111\/ane.12475-BIB0035|ane12475-cit-0035","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/ana.22137","article-title":"JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab","volume":"68","author":"Ryschkewitsch","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1111\/ane.12475-BIB0036|ane12475-cit-0036","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ana.23893","article-title":"JC virus antibody status underestimates infection rates","volume":"74","author":"Berger","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1111\/ane.12475-BIB0037|ane12475-cit-0037","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","article-title":"PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section","volume":"80","author":"Berger","year":"2013","journal-title":"Neurology"},{"key":"10.1111\/ane.12475-BIB0038|ane12475-cit-0038","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1212\/WNL.0b013e3182a351fb","article-title":"L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients","volume":"81","author":"Schwab","year":"2013","journal-title":"Neurology"},{"key":"10.1111\/ane.12475-BIB0039|ane12475-cit-0039","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ana.24153","article-title":"The CSF JCV antibody index for diagnosis of natalizumab-associated PML","volume":"76","author":"Warnke","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1111\/ane.12475-BIB0040|ane12475-cit-0040","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jamaneurol.2013.598","article-title":"Natalizumab: bench to bedside and beyond","volume":"70","author":"Rudick","year":"2013","journal-title":"JAMA Neurol"}],"container-title":["Acta Neurologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fane.12475","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ane.12475\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T07:48:52Z","timestamp":1671522532000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ane.12475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,8]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"URL":"https:\/\/doi.org\/10.1111\/ane.12475","archive":["Portico"],"relation":{},"ISSN":["0001-6314"],"issn-type":[{"value":"0001-6314","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9,8]]}}}